GlassScriptPhysician profile
John R Donaldson
NPI 1578517538
$3,125.53
in general payments reported to CMS, 2019-2025
12 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $663 · 2021: $355 · 2022: $232 · 2023: $409 · 2024: $186 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $839.81 | 2019-2024 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $808.28 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $450.34 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $255.26 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $214.91 | 2021-2023 | |
| Lundbeck LLC | $144.86 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $120.01 | 2024-2025 | Auvelity |
| Allergan, INC. | $115.20 | 2019 | |
| Acadia Pharmaceuticals INC | $79.12 | 2019-2023 | Nuplazid |
| Neurocrine Biosciences, INC. | $44.71 | 2021 | |
| Biosense Webster, INC. | $30.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Donaldson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.